Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBR 733

Next Previous
X
Search
Drug Profile

IBR 733

Alternative Names: Anti-CD33/CLL1 CAR NK cell therapy - Imbioray (Hangzhou) Biomedicine; IBR-733; IBR733 cell injection - Imbioray (Hangzhou) Biomedicine

Latest Information Update: 05 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imbioray (Hangzhou) Biomedicine
  • Developer Imbioray (Hangzhou) Biomedicine; Wuxi People's Hospital
  • Class Antineoplastics; CAR-NK cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Acute myeloid leukaemia

Most Recent Events

  • 31 Jan 2024 Imbioray (Hangzhou) Biomedicine plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in China (IV) in February 2024 (NCT06234904)
  • 03 Feb 2022 Phase-0 clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (Parenteral) (NCT05215015)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top